Logo Arcus Biosciences, Inc.

Arcus Biosciences, Inc. (RCUS) stock: analyst price target and their real reliability

Live quote · data updated Oct 14, 2026
Arcus Biosciences, Inc. · Health Care · ref. ETF XLV · 66 calls · price $22.51
🏆JPI 2026 portfoliosSee tracking →
What the company does: Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.

📈 Arcus Biosciences, Inc. (RCUS) stock price

$22.51+44.1% over range
Oct 14, 25low $15.62 · high $31.57Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
75% recommend buying · 8 analysts
📊 JPI status : Arcus Biosciences, Inc. is currently in 🎯 JPI Fair n°10. Also present in past years.

🎯 RCUS price target & analyst consensus — price $22.51

The price target · all analysts combined (7 targets)
Highest target · 1 firm of 7$46+104.4%
Median target · of 7 targets$40+77.7%
Lowest target · 1 firm of 7$22-2.3%
Current price$22.51
Where these 7 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price 686% $26 ↔ $46
Below 114% $22
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: HC Wainwright & Co. — 60% of its targets hit on this sector (329 calls tested). It aims for $45 (+100 %), call made on July 21, 2026, maturing on July 21, 2027 (85 d ago).

The 1 reliable analyst $45+100 %
The 6 other firms $37+64 %
How to read it: the 1 reliable firms are not filtered by optimism — 1 aim above the price, 0 below, hence their $45 median. “The 6 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 8 ratings (last 6 months)
Strong Buy00%
Buy675%
Hold225%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about Arcus Biosciences, Inc.? The JPI assistant answers using our backtest data.

🔎 Detailed analyses

✅ Historical analyst reliability on RCUS

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm ↕ % right i ↕ Gain vs sector i ↕ Calls i ↕
SunTrust Robinson Humphrey 100% +145.5% 2
Wells Fargo ↗ 67% +133.5% 3
Morgan Stanley ↗ 57% +55.2% 7
BTIG ↗ 50% -9.7% 2
Barclays ↗ 43% +24.3% 7
SVB Leerink 40% -4.2% 10
Mizuho ↗ 33% +5.1% 6
Cantor Fitzgerald ↗ 25% +0.7% 8
Truist Securities ↗ 20% -17.5% 5
Citigroup ↗ 11% -24.8% 9
See the other 1 firms
Wedbush ↗ 0% -27.5% 8

📊 What $1,000 invested in Arcus Biosciences, Inc. would be worth › open the full page

In short — $1,000 invested in Arcus Biosciences, Inc. 10 years ago would be worth $1,610 today, i.e. +6%/yr on average. Best year: 2020 (+168%), worst: 2022 (-49%). Price performance, excluding dividends.

If I'd invested $1,000 in Arcus Biosciences, Inc.

InvestmentWorth todayGain
1 years ago$1,881+88%
3 years ago$1,370+37%
5 years ago$1,091+9%
→ See Arcus Biosciences, Inc.'s full return history + gain calculator

Return by year (Arcus Biosciences, Inc.)

YearReturn$1,000 invested at year start
2026 (YTD)+22%$1,216 (+22%)
2025+55%$1,881 (+88%)
2024-21%$1,483 (+48%)
→ See Arcus Biosciences, Inc.'s full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on Arcus Biosciences, Inc.

Loading news…

📋 All analyst calls on RCUS

Wedbush ↗
Sep 30, 26
▲ Outperform · 🎯$43
Price at call : $25.83 — upside +66%
Today : $22.51 — upside +91%
🎯 on RCUS : 0% (8 calls matureds) · 📊 on Health : 37% · +6.7% (54 calls)
in progress (365j)
matures : Sep 30, 27
TD Cowen ↗
Sep 16, 26
▲ Buy
🎯 on RCUS : no call matured yet · 📊 on Health : 50% · -1.0% (40 calls)
in progress (365j)
matures : Sep 16, 27
▲ Buy · 🎯$40
Price at call : $28.49 — upside +40%
Today : $22.51 — upside +78%
🎯 on RCUS : 50% (2 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
in progress (365j)
matures : Sep 8, 27
Wells Fargo ↗
Aug 6, 26
■ Equal-Weight neutral · not a buy · 🎯$26
Price at call : $28.62 — gap to target -9%
Today : $22.51 — gap to target +16%
🎯 on RCUS : 67% (3 calls matureds) · 📊 on Health : 38.3% · +2.0% (107 calls)
in progress (365j)
matures : Aug 6, 27
Wedbush ↗
Aug 6, 26
▲ Outperform · 🎯$43
Price at call : $28.62 — upside +50%
Today : $22.51 — upside +91%
🎯 on RCUS : 0% (8 calls matureds) · 📊 on Health : 37% · +6.7% (54 calls)
in progress (365j)
matures : Aug 6, 27
▲ Buy · 🎯$45
Price at call : $28.17 — upside +60%
Today : $22.51 — upside +100%
🎯 on RCUS : 100% (1 call matured) · 📊 on Health : 57.4% · +25.1% (329 calls)
in progress (365j)
matures : Jul 20, 27
▲ Outperform · 🎯$46
Price at call : $23.19 — upside +98%
Today : $22.51 — upside +104%
🎯 on RCUS : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Jun 4, 27
Morgan Stanley ↗
May 11, 26
■ Equal-Weight neutral · not a buy · 🎯$22
Price at call : $24.9 — gap to target -12%
Today : $22.51 — gap to target -2%
🎯 on RCUS : 75% (4 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : May 11, 27
See the other 58 calls, newest to oldest
Goldman Sachs ↗
May 7, 26
▲ Buy · 🎯$34
Price at call : $25.36 — upside +34%
Today : $22.51 — upside +51%
🎯 on RCUS : no call matured yet · 📊 on Health : 51.9% · +5.8% (104 calls)
in progress (365j)
matures : May 7, 27
Wedbush ↗
Apr 2, 26
▲ Outperform · 🎯$41
Price at call : $22.96 — upside +79%
Today : $22.51 — upside +82%
🎯 on RCUS : 0% (8 calls matureds) · 📊 on Health : 37% · +6.7% (54 calls)
in progress (365j)
matures : Apr 2, 27
Citigroup ↗
Mar 5, 26
▲ Buy · 🎯$45
Price at call : $22.11 — upside +104%
Today : $22.51 — upside +100%
🎯 on RCUS : 0% (1 call matured) · 📊 on Health : 44.9% · -4.4% (107 calls)
in progress (365j)
matures : Mar 5, 27
▲ Outperform · 🎯$49
Price at call : $22.43 — upside +118%
Today : $22.51 — upside +118%
🎯 on RCUS : no call matured yet · 📊 on Health : 54.5% · +7.0% (11 calls)
in progress (365j)
matures : Mar 2, 27
▲ Buy · 🎯$32
Price at call : $23.94 — upside +34%
Today : $22.51 — upside +42%
🎯 on RCUS : 100% (1 call matured) · 📊 on Health : 57.4% · +25.1% (329 calls)
in progress (365j)
matures : Mar 2, 27
Wells Fargo ↗
Feb 12, 26
■ Equal-Weight neutral · not a buy · 🎯$23
Price at call : $19.96 — gap to target +15%
Today : $22.51 — gap to target +2%
🎯 on RCUS : 67% (3 calls matureds) · 📊 on Health : 38.3% · +2.0% (107 calls)
in progress (365j)
matures : Feb 12, 27
Goldman Sachs ↗
Jan 13, 26
▲ Buy · 🎯$28
Price at call : $24.56 — upside +14%
Today : $22.51 — upside +24%
🎯 on RCUS : no call matured yet · 📊 on Health : 51.9% · +5.8% (104 calls)
in progress (365j)
matures : Jan 13, 27
■ Equal-Weight neutral · not a buy · 🎯$20
Price at call : $21.35 — gap to target -6%
Today : $22.51 — gap to target -11%
🎯 on RCUS : 75% (4 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Jan 8, 27
▲ Buy · 🎯$32
Price at call : $21.91 — upside +46%
Today : $22.51 — upside +42%
🎯 on RCUS : 100% (1 call matured) · 📊 on Health : 57.4% · +25.1% (329 calls)
in progress (365j)
matures : Dec 12, 26
■ Neutral neutral · not a buy · 🎯$26
Price at call : $26.1 — gap to target -0%
Today : $22.51 — gap to target +16%
🎯 on RCUS : no call matured yet · 📊 on Health : 51.9% · +3.9% (156 calls)
in progress (365j)
matures : Nov 28, 26
Goldman Sachs ↗
Oct 30, 25
■ Neutral neutral · not a buy · 🎯$16
Price at call : $19.72 — gap to target -19%
Today : $22.51 — gap to target -29%
🎯 on RCUS : no call matured yet · 📊 on Health : 51.9% · +5.8% (104 calls)
in progress (365j)
matures : Oct 30, 26
Citigroup ↗
Oct 29, 25
▲ Buy · 🎯$56
Price at call : $20.19 — upside +177%
Today : $22.51 — upside +149%
🎯 on RCUS : 0% (1 call matured) · 📊 on Health : 44.9% · -4.4% (107 calls)
in progress (365j)
matures : Oct 29, 26
▲ Buy · 🎯$28
Price at call : $20.29 — upside +38%
Today : $22.51 — upside +24%
🎯 on RCUS : 100% (1 call matured) · 📊 on Health : 57.4% · +25.1% (329 calls)
in progress (365j)
matures : Oct 29, 26
Wells Fargo ↗
Oct 20, 25
▲ Overweight · 🎯$29
Price at call : $18.05 — upside +61%
Today : $22.51 — upside +29%
🎯 on RCUS : 67% (3 calls matureds) · 📊 on Health : 38.3% · +2.0% (107 calls)
in progress (365j)
matures : Oct 20, 26
Citigroup ↗
Oct 13, 25
▲ Buy · 🎯$54
Price at call : $15.62 — upside +246%
Today : $22.51 — upside +140%
🎯 on RCUS : 0% (1 call matured) · 📊 on Health : 44.9% · -4.4% (107 calls)
in progress (365j)
matures : Oct 13, 26
▲ Buy · 🎯$39
Price at call : $15.05 — upside +159%
Today : $22.51 — upside +73%
Expected +159% · Actual +58% · Reason (≥ +15%) : ✓ Yes
🎯 on RCUS : 50% (2 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
+58.3%
stock +58% · XLV +16%
matured Oct 7, 26
▲ Overweight · 🎯$23
Price at call : $9.06 — upside +154%
Today : $22.51 — upside +2%
Expected +154% · Actual +217% · Reason (≥ +15%) : ✓ Yes
🎯 on RCUS : 75% (4 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
+217.0%
stock +217% · XLV +29%
matured Aug 7, 26
Wells Fargo ↗
Aug 7, 25
▲ Overweight · 🎯$25
Price at call : $9.06 — upside +176%
Today : $22.51 — upside +11%
Expected +176% · Actual +217% · Reason (≥ +15%) : ✓ Yes
🎯 on RCUS : 67% (3 calls matureds) · 📊 on Health : 38.3% · +2.0% (107 calls)
+217.0%
stock +217% · XLV +29%
matured Aug 7, 26
▲ Overweight · 🎯$22
Price at call : $8.8 — upside +150%
Today : $22.51 — upside -2%
Expected +150% · Actual +183% · Reason (≥ +15%) : ✓ Yes
🎯 on RCUS : 75% (4 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
+182.5%
stock +183% · XLV +5%
matured May 9, 26
Goldman Sachs ↗
May 8, 25
■ Neutral neutral · not a buy · 🎯$13
Price at call : $8.28 — gap to target +57%
Today : $22.51 — gap to target -42%
🎯 on RCUS : no call matured yet · 📊 on Health : 51.9% · +5.8% (104 calls)
in progress (365j)
matures : May 8, 26
Wells Fargo ↗
May 7, 25
▲ Overweight · 🎯$26
Price at call : $8.53 — upside +205%
Today : $22.51 — upside +16%
Expected +205% · Actual +197% · Reason (≥ +15%) : ✓ Yes
🎯 on RCUS : 67% (3 calls matureds) · 📊 on Health : 38.3% · +2.0% (107 calls)
+197.3%
stock +197% · XLV +7%
matured May 7, 26
Barclays ↗
Apr 23, 25
▲ Overweight · 🎯$14
Price at call : $8.11 — upside +73%
Today : $22.51 — upside -38%
Expected +73% · Actual +210% · Reason (≥ +15%) : ✓ Yes
🎯 on RCUS : 67% (3 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
+209.9%
stock +210% · XLV +8%
matured Apr 23, 26
▲ Buy · 🎯$24
Price at call : $10.14 — upside +137%
Today : $22.51 — upside +7%
Expected +137% · Actual +93% · Reason (≥ +15%) : ✓ Yes
🎯 on RCUS : 100% (1 call matured) · 📊 on Health : 57.4% · +25.1% (329 calls)
+92.7%
stock +93% · XLV +6%
matured Feb 26, 26
■ Neutral neutral · not a buy · 🎯$17
Price at call : $11.1 — gap to target +53%
Today : $22.51 — gap to target -24%
🎯 on RCUS : no call matured yet · 📊 on Health : 51.9% · +3.9% (156 calls)
in progress (365j)
matures : Feb 19, 26
■ Neutral neutral · not a buy · 🎯$18
Price at call : $11.1 — gap to target +62%
Today : $22.51 — gap to target -20%
🎯 on RCUS : 100% (1 call matured) · 📊 on Health : 57.4% · +25.1% (329 calls)
in progress (365j)
matures : Feb 18, 26
Morgan Stanley ↗
Feb 18, 25
▲ Overweight · 🎯$25
Price at call : $11.1 — upside +125%
Today : $22.51 — upside +11%
Expected +125% · Actual +76% · Reason (≥ +15%) : ✓ Yes
🎯 on RCUS : 75% (4 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
+75.5%
stock +76% · XLV +7%
matured Feb 18, 26
■ Neutral neutral · not a buy · 🎯$20
Price at call : $15.73 — gap to target +27%
Today : $22.51 — gap to target -11%
🎯 on RCUS : 100% (1 call matured) · 📊 on Health : 57.4% · +25.1% (329 calls)
in progress (365j)
matures : Nov 6, 25
Barclays ↗
Oct 25, 24
▲ Overweight · 🎯$29
Price at call : $16.66 — upside +74%
Today : $22.51 — upside +29%
Expected +74% · Actual +12% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 67% (3 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
+11.6%
stock +12% · XLV -2%
matured Oct 25, 25
■ Neutral neutral · not a buy · 🎯$20
Price at call : $16.32 — gap to target +23%
Today : $22.51 — gap to target -11%
🎯 on RCUS : 100% (1 call matured) · 📊 on Health : 57.4% · +25.1% (329 calls)
in progress (365j)
matures : Oct 24, 25
■ Neutral neutral · not a buy · 🎯$20
Price at call : $16.97 — gap to target +18%
Today : $22.51 — gap to target -11%
🎯 on RCUS : 100% (1 call matured) · 📊 on Health : 57.4% · +25.1% (329 calls)
in progress (365j)
matures : Oct 21, 25
Wells Fargo ↗
Oct 8, 24
▲ Overweight · 🎯$29
Price at call : $17.47 — upside +66%
Today : $22.51 — upside +29%
Expected +66% · Actual -14% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 67% (3 calls matureds) · 📊 on Health : 38.3% · +2.0% (107 calls)
-13.9%
stock -14% · XLV -5%
matured Oct 8, 25
▲ Overweight
Actual -14% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 25% (8 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
-13.9%
stock -14% · XLV -5%
matured Oct 7, 25
▲ Overweight
Actual -13% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 25% (8 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
-13.0%
stock -13% · XLV -5%
matured Oct 3, 25
Wedbush ↗
Oct 3, 24
▲ Outperform · 🎯$30
Price at call : $16.65 — upside +80%
Today : $22.51 — upside +33%
Expected +80% · Actual -13% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 0% (8 calls matureds) · 📊 on Health : 37% · +6.7% (54 calls)
-13.0%
stock -13% · XLV -5%
matured Oct 3, 25
▲ Overweight
Actual -39% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 25% (8 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
-38.7%
stock -39% · XLV -13%
matured Aug 9, 25
Wedbush ↗
Aug 9, 24
▲ Outperform · 🎯$30
Price at call : $14.95 — upside +101%
Today : $22.51 — upside +33%
Expected +101% · Actual -39% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 0% (8 calls matureds) · 📊 on Health : 37% · +6.7% (54 calls)
-38.7%
stock -39% · XLV -13%
matured Aug 9, 25
■ Neutral neutral · not a buy · 🎯$23
Price at call : $15.61 — gap to target +47%
Today : $22.51 — gap to target +2%
🎯 on RCUS : no call matured yet · 📊 on Health : 51.9% · +3.9% (156 calls)
in progress (365j)
matures : Aug 9, 25
Barclays ↗
Jul 8, 24
▲ Overweight · 🎯$25
Price at call : $14.08 — upside +78%
Today : $22.51 — upside +11%
Expected +78% · Actual -34% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 67% (3 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
-33.7%
stock -34% · XLV -7%
matured Jul 8, 25
▲ Overweight
Actual -41% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 25% (8 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
-40.6%
stock -41% · XLV -7%
matured Jul 5, 25
▲ Buy · 🎯$44
Price at call : $15.83 — upside +178%
Today : $22.51 — upside +95%
Expected +178% · Actual -46% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 50% (2 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
-45.6%
stock -46% · XLV -9%
matured Jun 24, 25
Citigroup ↗
Jun 3, 24
▲ Buy · 🎯$38
Price at call : $16 — upside +138%
Today : $22.51 — upside +69%
Expected +138% · Actual -40% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 0% (1 call matured) · 📊 on Health : 44.9% · -4.4% (107 calls)
-40.0%
stock -40% · XLV -8%
matured Jun 3, 25
Morgan Stanley ↗
May 13, 24
▲ Overweight · 🎯$40
Price at call : $17.21 — upside +132%
Today : $22.51 — upside +78%
Expected +132% · Actual -50% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 75% (4 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
-49.6%
stock -50% · XLV -8%
matured May 13, 25
Wedbush ↗
May 9, 24
▲ Outperform · 🎯$30
Price at call : $16.15 — upside +86%
Today : $22.51 — upside +33%
Expected +86% · Actual -49% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 0% (8 calls matureds) · 📊 on Health : 37% · +6.7% (54 calls)
-48.7%
stock -49% · XLV -7%
matured May 9, 25
Wedbush ↗
Feb 22, 24
▲ Outperform · 🎯$30
Price at call : $19.67 — upside +53%
Today : $22.51 — upside +33%
Expected +53% · Actual -44% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 0% (8 calls matureds) · 📊 on Health : 37% · +6.7% (54 calls)
-43.7%
stock -44% · XLV -1%
matured Feb 21, 25
Wedbush ↗
Jan 30, 24
▲ Outperform · 🎯$30
Price at call : $15.14 — upside +98%
Today : $22.51 — upside +33%
Expected +98% · Actual -12% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 0% (8 calls matureds) · 📊 on Health : 37% · +6.7% (54 calls)
-11.6%
stock -12% · XLV +5%
matured Jan 29, 25
Mizuho ↗
Jan 30, 24
▲ Buy · 🎯$42
Price at call : $15.14 — upside +177%
Today : $22.51 — upside +87%
Expected +177% · Actual -12% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 33% (6 calls matureds) · 📊 on Health : 27.3% · -9.0% (88 calls)
-11.6%
stock -12% · XLV +5%
matured Jan 29, 25
Wedbush ↗
Jan 17, 24
▲ Outperform · 🎯$36
Price at call : $17 — upside +112%
Today : $22.51 — upside +60%
Expected +112% · Actual -17% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 0% (8 calls matureds) · 📊 on Health : 37% · +6.7% (54 calls)
-16.9%
stock -17% · XLV +1%
matured Jan 16, 25
▲ Overweight · 🎯$36
Price at call : $13.74 — upside +162%
Today : $22.51 — upside +60%
Expected +162% · Actual +30% · Reason (≥ +15%) : ✓ Yes
🎯 on RCUS : 25% (8 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
+29.9%
stock +30% · XLV +20%
matured Nov 7, 24
Mizuho ↗
Oct 3, 23
▲ Buy · 🎯$51
Price at call : $15.82 — upside +222%
Today : $22.51 — upside +127%
Expected +222% · Actual -3% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 33% (6 calls matureds) · 📊 on Health : 27.3% · -9.0% (88 calls)
-3.2%
stock -3% · XLV +18%
matured Oct 2, 24
▲ Overweight · 🎯$46
Price at call : $21.25 — upside +116%
Today : $22.51 — upside +104%
Expected +116% · Actual -20% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 25% (8 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
-20.1%
stock -20% · XLV +17%
matured Sep 11, 24
▲ Overweight · 🎯$46
Price at call : $21.38 — upside +115%
Today : $22.51 — upside +104%
Expected +115% · Actual -24% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 25% (8 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
-23.7%
stock -24% · XLV +17%
matured Sep 6, 24
Mizuho ↗
Aug 23, 23
▲ Buy · 🎯$51
Price at call : $22.92 — upside +123%
Today : $22.51 — upside +127%
Expected +123% · Actual -21% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 33% (6 calls matureds) · 📊 on Health : 27.3% · -9.0% (88 calls)
-21.4%
stock -21% · XLV +17%
matured Aug 22, 24
Wedbush ↗
May 10, 23
▲ Outperform · 🎯$36
Price at call : $18.02 — upside +100%
Today : $22.51 — upside +60%
Expected +100% · Actual -7% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 0% (8 calls matureds) · 📊 on Health : 37% · +6.7% (54 calls)
-7.3%
stock -7% · XLV +8%
matured May 9, 24
Mizuho ↗
Mar 17, 23
▲ Buy · 🎯$51
Price at call : $16.45 — upside +210%
Today : $22.51 — upside +127%
Expected +210% · Actual +5% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 33% (6 calls matureds) · 📊 on Health : 27.3% · -9.0% (88 calls)
+4.7%
stock +5% · XLV +15%
matured Mar 16, 24
Mizuho ↗
May 14, 20
▲ Buy · 🎯$40
Price at call : $31.79 — upside +26%
Today : $22.51 — upside +78%
Expected +26% · Actual -10% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 33% (6 calls matureds) · 📊 on Health : 27.3% · -9.0% (88 calls)
-10.3%
stock -10% · XLV +24%
matured May 14, 21
▲ Overweight · 🎯$21
Price at call : $14.44 — upside +45%
Today : $22.51 — upside -7%
Expected +45% · Actual +126% · Reason (≥ +15%) : ✓ Yes
🎯 on RCUS : 25% (8 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
+125.6%
stock +126% · XLV +35%
matured Apr 3, 21
Mizuho ↗
Sep 27, 19
▲ Buy · 🎯$22
Price at call : $10.18 — upside +116%
Today : $22.51 — upside -2%
Expected +116% · Actual +72% · Reason (≥ +15%) : ✓ Yes
🎯 on RCUS : 33% (6 calls matureds) · 📊 on Health : 27.3% · -9.0% (88 calls)
+72.3%
stock +72% · XLV +16%
matured Sep 26, 20
Wedbush ↗
Oct 9, 18
▲ Outperform · 🎯$22
Price at call : $13.3 — upside +65%
Today : $22.51 — upside -2%
Expected +65% · Actual -40% · Reason (≥ +15%) : ✗ No
🎯 on RCUS : 0% (8 calls matureds) · 📊 on Health : 37% · +6.7% (54 calls)
-40.1%
stock -40% · XLV -6%
matured Oct 9, 19

Frequently asked questions

Should I buy Arcus Biosciences, Inc. stock?

This isn't buy advice. For Arcus Biosciences, Inc., the analyst consensus is "Buy", with an average price target of $40.00 (+78% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (2 calls tracked on Arcus Biosciences, Inc.). We show the numbers — you decide.

Is it too late to buy Arcus Biosciences, Inc.? How high can it go?

The most bullish analyst target on Arcus Biosciences, Inc. is $46.00 (+104% above today's price); the average is $40.00. That's the upside they see. Check how reliable those analysts have actually been on Arcus Biosciences, Inc. on our site before trusting it.

Is Arcus Biosciences, Inc. still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 11 analysts have a real record on Arcus Biosciences, Inc., the best hitting 100% over 2 calls. Current consensus: "Buy". Make your call on data, not noise.

Should you invest in Arcus Biosciences, Inc.? The case for and against

The arguments for and against, one by one, from the numbers: why invest in RCUS (and why hesitate).

What has Arcus Biosciences, Inc.'s past performance been?

Historical returns and a "how much if I had invested" calculator: RCUS performance & returns.

What is the best month to buy RCUS?

The 12 months ranked by the stock's past returns: best & worst month to buy RCUS.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)